Trial Profile
A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Ivacaftor/tezacaftor (Primary) ; Ivacaftor
- Indications Cystic fibrosis
- Focus Adverse reactions; Registrational
- Sponsors Vertex Pharmaceuticals
- 17 Jan 2023 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 03 Jan 2023 Status changed from active, no longer recruiting to completed.
- 19 Dec 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.